Clinical Trial

A Real-World Study of Trastuzumab Rezetecan in HER2+ Solid Tumors

Name: A Real-World Study of Trastuzumab Rezetecan in HER2+ Solid Tumors — clinical trial record (NCT07387874)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting

View on ClinicalTrials.gov →

Summary

To Observe and Evaluate the Safety Profile of Trastuzumab Rezetecan Alone or in Combination in Patients with HER-2 Protein-Expressing Recurrent or Metastatic Malignant Solid Tumors in a Real-World Setting.

Trial Details

NCT Number	NCT07387874
Lead Sponsor	Lixiaoling
Conditions	Recurrent or Metastatic Solid Tumors
Enrollment	30 participants
Start Date	2025-07-10
Primary Completion	2027-07 (estimated)
Study Completion	2028-07 (estimated)
Updated on ClinicalTrials.gov	2026-02-04